Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 3:13:1067289.
doi: 10.3389/fonc.2023.1067289. eCollection 2023.

Advances in the treatment of Hodgkin lymphoma: Current and future approaches

Fauzia Ullah  1 , Danai Dima  1   2 , Najiullah Omar  1 , Olisaemeka Ogbue  1 , Sairah Ahmed  3
Affiliations
Review

Advances in the treatment of Hodgkin lymphoma: Current and future approaches

Fauzia Ullah et al. Front Oncol. .

Abstract

Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin's lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.

Keywords: Classical Hodgkin lymphoma (cHL); chemoimmunotherapy; chimeric antigen receptor (CAR) T-cell therapy; hematopoietic stem cell transplant; relapsed and refractory Hodgkin's lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Flora DR, Parsons SK, Liu N, Yu KS, Holmes K, Flores C, et al. Classical Hodgkin lymphoma; real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT)-a cross-sectional survey of patients with stage III or IV classical Hodgkin lymphoma compared by age. Blood (2021) 138(Supplement 1):1966–6. doi: 10.1182/blood-2021-147354 - DOI
    1. Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J haematology (2019) 184(1):45–59. doi: 10.1111/bjh.15614 - DOI - PMC - PubMed
    1. Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol (2013) 31(2):256–62. doi: 10.1200/JCO.2011.39.9881 - DOI - PMC - PubMed
    1. Liu Y, Abdul Razak FR, Terpstra M, Chan FC, Saber A, Nijland M, et al. The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia (2014) 28(11):2248–51. doi: 10.1038/leu.2014.201 - DOI - PubMed
    1. Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet (British edition) (2021) 398(10310):1518–27. doi: 10.1016/S0140-6736(20)32207-8 - DOI - PubMed

LinkOut - more resources